We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Lluís Montoliu (CNB-CSIC).
Lluis Montoliu is a CSIC Research Scientist at the National Centre for Biotechnology and at the Spanish Research Initiative on Rare Diseases, in Madrid, Spain after working in Heidelberg and Barcelona. He is the Director of the Spanish node of the European Mouse Mutant Archive (EMMA/INFRAFRONTIER). At the CNB, since 1997, he leads a research team interested in basic science (genome organization), and in applied biomedical science, using animal models for the study of human rare diseases, such as albinism. He has pioneered the in vivo use of genome-editing CRISPR approaches in Spain. He is the current President of two scientific societies ESPCR and ARRIGE and serves at the boards of additional national and international associations. He is the President of the CSIC Ethics Committee and serves at the Ethics Panel of ERC. Besides research, he is also interested in ethics, education and popular science.Laboratory has generated numerous animal models of human rare diseases, such as albinism, through standard genetic modifications or using CRISPR-Cas9 genome editing tools, whose use in mice he pioneered in Spain. He is the President of the CSIC Ethics Committee and a member of the Ethics Panel at the ERC in Brussels.
Genome editing is firmly progressing to the clinic, with an increasing number of clinical trials following numerous preclinical experiments where a variety of CRISPR-related tools have been assessed. Innovation is also arriving at the level of delivery systems, with the use of nanotechnology, thanks to the great success obtained with the lipid nanoparticles that were used to encapsulate the mRNA encoding the S protein of the coronavirus. This webinar will review where do we stand today in genome editing, aims achieved and remaining challenges.
Host: Dr. Josep Quer Sivila, Main researcher, Liver Diseases, Vall Hebron Institut de Recerca VHIR
Registre Online: https://gencat.zoom.us/webinar/register/WN_zRJXco6JSdqP2ji_Y4DwGg
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.